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PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple
myeloma.
MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the
period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17)
and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed.
RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years;
mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence
was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral
column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms
until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39
months (mean ± SD), and the progression rate was 57%.
CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences
were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most
affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple
myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma
or for those who progressed to multiple myeloma.
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INTRODUCTION
MacIntyre1 described in 1850 the first case of Molli-
ties et Fragilitas Ossium, and in 1873 Rustizky2 wrote the
first definitive pathological description of the disease, pro-
posing the name myeloma, which was consolidated by
Kahler3 in 1889. Multiple myeloma was recognized as hav-
ing a combination of indicators, including osseous deform-
ity, fragility and pain, cachexia, and Bence Jones protein
in the urine.
Later, the use of radiography facilitated diagnosing the
disease. Radiographic evaluation showed that the disease
is characterized by well-defined osteolytic areas without
the presence of bone proliferation or sclerosis.
According to the current definition issued by the World
Health Organization, multiple myeloma is a malignant
tumor with multiple or diffuse involvement of the bone with
neoplastic plasma cells having different degrees of imma-
turity including atypical forms. Lesions are often associ-
ated with abnormal presence of proteins in blood and urine
and, occasionally, with the presence of amyloid or para-
amyloid deposits in the tumoral tissue or other organs.
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The probable origin of plasmacytoma relates to muta-
genic changes in the development of the B lymphocyte.
Possibly, initial oncogenic mutations appear and establish
themselves during the late periods of lymphocytic devel-
opment (these lymphocytes multiply in large scale, form-
ing clones, and their characteristics may also be stored in
memory cells). The plasmocyte that originated from a mu-
tated lymphocyte and had its characteristics altered then
accommodates in the bone marrow.4 Radiation may induce
mutations that activate oncogenes, leading to the develop-
ment of multiple myeloma. This has been observed with
the increased incidence of myeloma in Hiroshima atomic
bomb survivors and in radiologists.5,6 Cytogenetical stud-
ies in patients with multiple myeloma showed that 68% of
samples presented numerical chromosomal alterations
(62%), structural alterations (31%), or both (7%).7
Multiple myeloma is generally associated with the pro-
duction by tumor cells of IgG or IgA monoclonal immu-
noglobulin or of light chains (Bence Jones protein), while
the polypeptidic M protein can be detected in serum and/
or urine using immunohistochemical techniques.
As to incidence, in a review of cases of multiple my-
eloma studied between 1950 and 1975 in the USA, Blattner
et al8 found an incidence of 2 or 3 cases of multiple my-
eloma per 100,000 people, with highest incidence among
African American, whose mortality rate was also twice that
reported for Caucasians.9 According to the SEER Program,
multiple myeloma is responsible for 1.0% of all malignan-
cies in Caucasians and 2% in African Americans. The
yearly average (1970 US standard) incidence per 100,000
was 4.7 in Caucasian males and 3.2 in Caucasian females,
while for African Americans incidence was nearly doubled,
with 10.2 for men and 6.7 for women.10
In general, myeloma occurs in patients over 40, often
between 50 and 70 years of age.9 Around 1973, most cases
were in the 70 to 80 year age group, with no significant
numbers of patients under 40 years of age.5 This difference
is due to the improvement in diagnosis enabling patients
to discover their disease earlier. Recently, computerized
tomography and nuclear magnetic resonance imaging have
detected abnormalities in bones that were deemed normal
by simple radiographs.11
In the absence of treatment, the prognosis for multiple
myeloma survival is lower than 2 years. Patients will even-
tually die due to renal failure, severe anemia, infections,
or complications secondary to neurologic problems.9,12
Plasmacytoma or solitary myeloma is characterized by
a single focus, generally in a long bone or a vertebral body.
The difference between solitary myeloma and multiple
myeloma is that the former does not present other
radiologically proven lesions and does present an absence
of changes in dysproteinemia and in proteinuria, as well
as a negative biopsy from the sternal medulla.9 Other cri-
teria are the absence of anemia, absence of hypercalcemia,
and absence of renal involvement.11,13 Plasmacytoma may
involve any bone, but it is more common in vertebrae
(33.3% of patients).11,15 Plasmacytoma is more common in
men. The age at the time of diagnosis has been reported
to be less than the age of typical multiple myeloma pa-
tients11,14-15 (Figure 1). The therapeutic results are better and
the prognosis is more favorable for plasamcytoma than for
multiple myeloma.14
As to treatment, radiotherapy is the first modality used
for plasmacytoma. The recommended dose of radiation is
5000-6000 cGy for 5 to 7 weeks. Regarding chemotherapy,
Holland et al16 reported that it delays the conversion time
of plasmacytoma to myeloma. With chemotherapy, the av-
erage time to conversion was 59 months, versus 29 months
in the group without chemotherapy; however, its use did
not reduce the conversion rate, since 64% of patients who
received chemotherapy converted to myeloma, while 41%
of patients who did not receive chemotherapy presented
conversion. Moreover, after conversion, patients who re-
ceived chemotherapy had the same survival time as patients
who did not receive this therapy.16 Currently, surgery is also
used as well as a combination of chemotherapy and radio-
therapy.9
Another recent type of treatment is the autologous stem
cell transplant, with a faster response rate and a longer dis-
ease-free survival time than with the conventional form of
chemotherapy (alkylating agents or vincristine, doxorubicin
and dexamethasone [VAD] alone) .17 Stem cell transplant
is a form of treatment for patients over 65 years of age
(50% of the patients with multiple myeloma) because high-
dose chemotherapy is not recommended for these patients,
due to age.18,19
The treatment for multiple myeloma has undergone 2
therapeutic advances, namely, the introduction of high-dose
Figure 1 -  Age (years) of patients with plasmacytoma at the time of the first
visit and of patients with plasmacytoma that progressed to multiple myeloma
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chemotherapy, which has proved to be more effective than
conventional chemotherapy, and the use of biphosphonates,
which decrease the odds ratio for vertebral fracture.20
In a study published by Bataille and Sany,13 53% of pa-
tients with plasmacytoma progressed to multiple myeloma,
with the average progression time being 31 months. In
some patients, the progression occurred only 17 years
later.16 The 10-year survival reached 68.5% for the cases
of plasmacytoma.21 This average survival time was better
than that found for patients with multiple myeloma who
were given alkylating agents only (average: 20 months)22
or a combination of antineoplastic drugs (average: 42
months).13,23
According to the clinical staging system developed by
Durie and Salmon,10,13,24 the prognosis for survival is bet-
ter for patients with plasmacytoma than for patients with
Phase I multiple myeloma. Over a 10-year follow-up pe-
riod, 85% of patients with plasmacytoma presented recur-
rences, either local, remote, or multiple, the latter being
responsible for 58% of the episodes.13,24 Although most pub-
lications mention that only 15% of patients with plasma-
cytoma remain stable for over 10 years, there is evidence
that about one third of patients remain free of multiple
myeloma for 10 years.11,25-28 Among the prognostic factors
are age, size of the injury, persistence of altered
immunoglobulins after radiotherapy, axial injury, early di-
agnosis, and the treatment employed.14
Currently there are no studies in Brazil about the pro-
gression of plasmacytoma to multiple myeloma; hence the
need for our study that aims to provide clinical and epide-
miological data obtained in our service concerning this neo-
plasia.
MATERIALS AND METHODS
A retrospective evaluation was performed that included
103 medical records of patients with anatomic pathologi-
cal diagnosis for bone plasmocytosis between 1950 and
1998.
The parameters considered were age, sex, anatomic lo-
cation, time of symptom onset, time to start of treatment,
type of treatment given, type of recurrence, time and rate
of progression to multiple myeloma, and survival time.
Sixty-three medical records were not used because of hav-
ing been lost to follow-up or for incompleteness; 10 were
not used because the disease in question was not plasma-
cytoma (4 of them were already multiple myeloma at the
time of diagnosis, and the others were cases of neuropa-
thy, falciform anemia, reactional plasmocytosis, non-Hodg-
kin’s lymphoma, and subacute osteomyelitis). Thirty medi-
cal records were used in the statistical analysis.
The statistical analysis included absolute (n) and rela-
tive (%) frequency distribution of the qualitative nominal
parameters. The nominal sample data were presented as
contingency tables for chi-square analysis (Table 1) and by
means of sector graphs. For the comparison of frequencies
between occurrences we used Fisher’s exact test. (tables 1
and 2; figures 2 and 3). To describe samples of the quanti-
tative ordinal parameters, we used descriptive statistics:
mean (M), standard deviation (SD), standard error of the
mean (SEM), maximum and minimum values, and the
number of cases (N). Ordinal data were presented in sta-
tistical tables and represented by column graphs (mean ±
Table 1 - Type of recurrence of primary tumors in patients
with plasmacytoma that progressed to myeloma (absolute
and relative (%) frequency distribution)






1 not referred to in the medical record
Chi square c2 = 6.0 P = 0.049*
Figure 2 - Sex in patients with plasmacytoma and in patients with
plasmacytoma that progressed to multiple myeloma (absolute and relative
(%) frequency distribution)
Table 2 - Sex of patients with plasmacytoma vs patients
with plasmacytoma that progressed to multiple myeloma
(absolute and relative (%) frequency distribution)
Sex Plasmacytoma Myeloma Total
n % n % n
Female 4 13.3 5 16.7 9
Male 9 30 12 40 21
TOTAL 13 43,3 17 56,7 30
Fisher’s exact test P = 1.00
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SEM) (tables 3, 4, 5, 6, and Figures 1, 4, 5, 6). To com-
pare average values (means), we used the Mann-Whitney
U test in case of samples with a nonparametric distribu-
tion, and Student’s t test for parametric samples.
Spearman’s nonparametric correlation test (r) was per-
formed on the ordinal parameters survival time (months)
and age (years). (Table 7). Qualitative nominal sample data
such as anatomic location and type of treatment were pre-
sented in descriptive tables, with no statistical analysis (ta-
bles 8 and 9; figures 7 and 8). A 5% significance level (a
Figure 3 - Absolute and relative (%) frequency distribution of the type of
recurrence of primary tumors in patients with plasmacytoma that progressed
to multiple myeloma
Table 3 - Time (days) from symptom onset until diagnosis
in patients with plasmacytoma vs patients with
plasmacytoma that progressed to multiple myeloma








1 not referred to in the medical chart
Mann-Whitney U test U = 59.0 P = 0.20
Table 4 - Age (in years) in patients with plasmacytoma at
the time of the first visit vs patients with plasmacytoma
that progressed to multiple myeloma
Age (years)
 Plasmacytoma  Myeloma
Mean 62.6  52.3
SD 12.2 10.9
SEM 3.4  2.6
MAX 85 69
MIN 47  27
N 13  17
Student’s t test t = 2.4 P = 0.02*
SD = standard deviation. SEM = standard error of the mean. N = number
of patients
Table 5 - Survival time (in months) in patients with
plasmacytoma vs patients with plasmacytoma that










 not referred to in the medical record
Mann-Whitney U test U = 63.5 P = 0.34
SD = standard deviation. SEM = standard error of the mean
Figure 5 - Survival time (months) in patients with plasmacytoma and in
patients with plasmacytoma that progressed to multiple myeloma (descriptive
statistics)
Figure 4 - Time (days) from first presentation with symptoms until diagnosis
in patients with plasmacytoma and in patients with plasmacytoma that
progressed to multiple myeloma (descriptive statistics)
Table 6 - Progression time (months) in patients with
plasmacytoma that progressed to multiple myeloma (descriptive
statistics)







1 not referred to in the medical record
143
CLINICS 2006;61(2):139-46 Oncologic progression of bone plasmacytomas to multiple myeloma
Bertanha F et al.
= 0.05) and 2-tailed tests were adopted. Results were
rounded according to scientific criteria. For the statistical
analysis we used the 2002 Microsoft Excel software
(Microsoft Corporation) and the 1996 GraphPad Prism
V.2.01 (GraphPad Software Inc.).
RESULTS
The average age at diagnosis of patients who progressed
to multiple myeloma was less than that of patients who did
not progress (52.3 ± 2.6 vs 62.6 ± 3.4 years (mean ± SEM),
respectively, P = 0.02).
There was a prevalence of the male sex in both groups
(patients who progressed to myeloma, 71%; patients who
did not progress, 69%; patients overall, 70%). No signifi-
cant difference was found between groups (P = 0.99)
There was a higher incidence of multiple recurrence
than of single recurrence of primary tumors in patients with
plasmacytoma that progressed to multiple myeloma (mul-
tiple recurrence, 75%; local recurrence, 6.2%; distant re-
currence, 19%; P = 0.049).
Regarding anatomical location, the vertebral column
was the most frequent location in both groups (61% and
47% in the plasmacytoma and multiple myeloma groups,
respectively).
Regarding the time from the onset of symptoms until
diagnosis, there was no significant difference between
groups (182 ± 53.2 vs 362.8 ± 130.2 days (mean ± SEM),
Figure 6 - Progression time (months) in patients with plasmacytoma that
progressed to multiple myeloma (descriptive statistics)
Table 7 - Correlation of progression time (months) and age
(years) (Spearman’s correlation test between quantitative
ordinal parameters)
                 PARAMETERS
Y X r p
Progression time Age 0.39 0.13
(months) (years)
Table 9 - Type of treatment received by patients with
plasmacytoma and by patients with plasmacytoma that
progressed to myeloma (absolute and relative (%) frequency
distribution)
Type of Plasmacytoma Myeloma Total
treatment n % n % n %
Surgery only 3 10.7 1 3.6 4 14.3
Chemotherapy only 0 0.0 0 0.0 0 0.0
Radiotherapy only 0 0.0 0 0.0 0 0.0
CT/RDT 3 10.7 2 7.1 5 17,9
RDT/Surgery 1 3.6 0 0.0 1 3,6
CT/Surgery 2 7.1 7 25.0 9 32.1
CT/RDT/Surgery 3 10.7 6 21.4 9 32.1
TOTAL 121 42.9 161 57.1 281 100.0
1 not referred to in the medical chart
CT: chemotherapy; RDT: radiotherapy
Figure 7 - Anatomic location of primary tumors in patients with
plasmacytoma and in patients with plasmacytoma that progressed to multiple
myeloma (absolute and relative (%) frequency distribution)
Figure 8 - Type of treatment received by patients with plasmacytoma and
by patients with plasmacytoma that progressed to multiple myeloma
(absolute and relative frequency distribution)
Table 8 - Anatomic location of primary tumors in patients
with plasmacytoma and in patients with plasmacytoma that
progressed to myeloma (absolute and relative (%) frequency
distribution)
Anatomic Plasmacytoma Myeloma Total
n % n % n %
Spinal Column 8 26.7 8 26.7 16 53.3
Clavicula 0 0 1 3.3 1 3.3
Humerus 1 3.3 3 10 4 13.3
Ilium 2 6.7 2 6.7 4 13.3
Femur 2 6.7 3 10 5 16.7
TOTAL 13 43.3 17 56.7 30 100
n = number of patients
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P = 0.34, for patients who did not progress vs patients who
did progress to multiple myeloma, respectively).
Regarding survival time, there was no difference be-
tween groups (57.4 ± 15 vs 78 ± 16.71 months (mean ±
SEM), P = 0.34, for patients who did not progress vs pa-
tients who did progress to multiple myeloma, respectively).
Regarding time to progression, the average was 41 ±
10 months (mean ± SEM). No correlation was found be-
tween the time to progression and age (P = 0.13). The pro-
gression rate of plasmacytoma to multiple myeloma was
57% (17 of 30 patients).
Regarding anatomic location, in the group with plas-
macytoma, we found the following: vertebral column, 62%;
humerus, 8%; pelvis, 15%; and femur, 15%. In the group
with plasmacytoma that progressed to multiple myeloma,
the values were as follows: vertebral column, 47%; cla-
vicula, 6%; humerus, 18%; pelvis, 12%; and femur, 18%.
Treatments administered to patients with plasmacytoma
were as follows: 25% surgery only; 25% chemotherapy and
radiotherapy; 8% radiotherapy and surgery; 17% chemo-
therapy and surgery; and 25% chemotherapy, radiotherapy,
and surgery. Treatments administered to patients with plas-
macytoma that progressed to multiple myeloma were as
follows: 6.25% surgery only; 12.5% chemotherapy and ra-
diotherapy; 43.75% chemotherapy and surgery; and 37.5%
chemotherapy, radiotherapy, and surgery.
Regarding survival time, there was no significant dif-
ference between groups (57.4 ± 15 vs 78.1± 16.7 months
(mean ± SEM), P = 0.34, for patients with plasmacytoma
vs patients who progressed to multiple myeloma, respec-
tively).
DISCUSSION
This study is part of an institutional effort to retrospec-
tively summarize some of our most significant patient se-
ries.29-31
Holland et al16 found a mean survival time of 10.7 years
for patients with plasmacytoma, whereas we found the sur-
vival time to average only 4.8 years. Olmo et al12 and
Schajowicz et al16 observed a mean survival time of 2 years
for patients who progressed to multiple myeloma, whereas
for our series, the mean survival time was 6.5 years. There-
fore, our results are different from those reported in litera-
ture, which might be explained by the fact that a small sam-
ple was used or because it was difficult to obtain data about
the progression of patients. In the study by Bataille et al.13
the authors mentioned that it was difficult to find a rela-
tionship between plasmacytoma and multiple myeloma be-
cause these are rare bone tumors.
From the statistical analysis performed we concluded that
patients who did not progress to multiple myeloma were
older than patients who did. In contrast to our findings, in
the study by Bataille et al,13 patients with plasmacytoma were
younger than those who had plasmacytoma that progressed
to myeloma (45.7 ± 9.5 vs 51.1 ± 12 years (mean ± SD),
respectively, P < 0.1). Additionally, Dimopoulos et al11 re-
port that patients with plasmacytoma were approximately 7
years younger than those with multiple myeloma
Regarding the frequency distribution of patients’ sex,
no statistically significant difference was found between
groups (plasmacytoma and plasmacytoma that progressed
to multiple myeloma), although in both groups the male
sex was more affected. Seventy percent of all patients were
men, which is in agreement with the data of Dimopoulos
et al11 and Holland et al.16
After analyzing the frequency distribution of the type
of recurrence of primary tumors in patients with plasma-
cytoma that progressed to multiple myeloma, we observed
a higher incidence (78%) of multiple recurrence, than that
(58%) found by Bataille and Sany.13 These authors observed
that 85% of patients showed progression to multiple my-
eloma, while in our study only 57% of patients showed this
progression, which is similar to the 53% found by Holland
et al,16 and to the 54% found by Frassica et al.27
We found the prevalence of vertebral column injuries
of 53%, a value higher than the 33.3% found by
Dimopoulos et al11 and the 34% found by Holland et al.16
According to Bataille and Sany,13 in patients with plasma-
cytoma, vertebral column injuries were found in 26.7% of
cases, while in patients with plasmacytoma who progressed
to multiple myeloma this percentage was 61.8% (P < 0.01),
which differs from the present study, where patients with
plasmacytoma that did not progress to multiple myeloma
presented more injuries in their vertebrae.
Regarding the time to progression, the average was 41
months compared to 31 months reported by Bataille and
Sany.13
CONCLUSION
Patients who progressed to multiple myeloma were
younger than those who did not; more than half of our pa-
tients progressed to multiple myeloma. There are no sig-
nificant differences between both groups in terms of sex,
time from symptom onset to diagnosis, or survival time.
The most affected anatomic location in both groups was
the vertebral column, and most patients were males. The
mean time to progression to multiple myeloma was 41
months, which was somewhat higher than previously re-
ported. Multiple recurrences were significantly more fre-
quent than single recurrences.
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RESUMO
Bertanha F, Boufelli G, Pires de Camargo O, Baptista AM,
Caiero MT, de Oliveira CRGCM, et al. Evolução oncoló-
gica dos plasmocitomas ósseos para mieloma múltiplo.
Clinics. 2006:61(2):139-46.
OBJETIVO: Avaliar os aspectos clínicos, diagnósticos,
fatores de prognóstico e porcentagem de evolução dos ca-
sos de plasmocitoma para mieloma múltiplo.
MATERIAS E MÉTODOS: Foram levantados 103 pron-
tuários do Hospital das Clínicas da FMUSP, entre os anos
de 1950 e 1998. Destes, 73 não foram utilizados por perda
de seguimento ou por apresentarem diagnóstico diferente
de plasmocitoma.
RESULTADOS: Concluímos que a idade dos pacientes que
evoluíram para mieloma múltiplo é inferior a dos pacien-
tes que não evoluíram. A média do primeiro grupo foi de
52,3 ± 2,6 anos e a do segundo 62,6 ± 3,4 anos (média ±
SEM; p=0,02). Não houve diferença estatística quanto ao
sexo. Analisando pacientes com plasmocitoma que evoluiu
para mieloma múltiplo, foi observada uma incidência maior
de recidivas múltiplas (75%, p=0,049). Em ambos os gru-
pos houve predominância de lesões da coluna vertebral.
Não houve nenhuma diferença significativa entre os gru-
pos com relação ao tempo de doença (desde o aparecimento
dos sintomas até o diagnóstico) (p=0,20) e à sobrevida
(p=0,34). Quanto ao tempo de evolução de plasmocitoma
para mieloma, a média foi de 41 meses (DP=38,8), com
uma taxa de evolução aproximadamente igual a 57%.
CONCLUSÃO: Os pacientes que evoluíram para mieloma
múltiplo são mais jovens. Não houve diferença significati-
va entre os dois grupos quanto ao sexo, tempo de doença
e tempo de sobrevida. Em ambos os grupos a localização
anatômica mais acometida foi a coluna vertebral. O tem-
po médio de evolução para mieloma múltiplo foi de 41
meses. Não foi possível calcular os fatores que influem na
sobrevida dos pacientes com plasmocitoma e dos pacien-
tes com plasmocitoma que evoluiu para mieloma múltiplo.
UNITERMOS: Plasmocitoma. Mieloma Múltiplo. Evolu-
ção clínica. Prognóstico. Células plasmáticas.
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